VRCDF (Verici Dx) Interest Expense : $-0.03 Mil (TTM As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Verici Dx Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Verici Dx's interest expense for the six months ended in Jun. 2024 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2024 was $-0.03 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Verici Dx's Operating Income for the six months ended in Jun. 2024 was $ -1.45 Mil. Verici Dx's Interest Expense for the six months ended in Jun. 2024 was $ -0.01 Mil. Verici Dx did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Verici Dx Interest Expense Historical Data

The historical data trend for Verici Dx's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verici Dx Interest Expense Chart

Verici Dx Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

-0.01

-0.03

Verici Dx Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Interest Expense	Get a 7-Day Free Trial			-	-0.01	-0.02	-0.01	-0.01

Verici Dx Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.03 Mil.

Verici Dx (OTCPK:VRCDF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Verici Dx's Interest Expense for the six months ended in Jun. 2024 was $-0.01 Mil. Its Operating Income for the six months ended in Jun. 2024 was $-1.45 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2024 was $0.27 Mil.

Verici Dx's Interest Coverage for the quarter that ended in Jun. 2024 is calculated as

Verici Dx did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Verici Dx Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Verici Dx PLC (OTCPK:VRCDF) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

VRCI:UK 63V:Germany

Address

19 Stanwell Road, Avon House, Penarth, Cardiff, GBR, CF64 2EZ

Website

https://www.vericidx.com

Verici Dx PLC is an immuno-diagnostics development company. The company is focused on developing diagnostics technologies that will help understand the outcomes of an organ transplant surgery. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; and Tuteva, a post-transplant diagnostic focused upon acute cellular rejection including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.

Verici Dx Headlines

No Headlines